May 07, 2014
Gilead Announces $5 Billion Share Repurchase Program
-- Provides Update on Buyback Program Initiated in
Purchases may be made through the open market and private block
transactions pursuant to Rule 10b5-1 plans, privately negotiated
transactions or other means as determined by Gilead’s management and in
accordance with the requirements of the
The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including our
ability to consummate repurchases under the share repurchase program due
to changes in our stock price, corporate or other market conditions. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead's Annual Report
on Form 10-K for the year ended
For more information on
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)